ERBB2 and neoplasm: HER2-positivity is currently defined as intense protein overexpression in >10% of the tumor cells by IHC, or HER2 gene amplification by FISH in breast and gastroesophageal cancer [18]; these classification systems have been applied by most but not all studies, resulting in poor validation.